LABELS · 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
OPDIVO
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2026-08-12
- Captured
- 2026-09-09T23:37:42.544548+00:00
- Current indication reconciliation
- Not reconciled
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). (1.8) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma. 1.2 Adjuvant Treatment of Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. 1.3 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). 1.4 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery. 1.5 Metastatic Non-Small Cell Lung Cancer • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations. • OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations. • OPDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. 1.6 Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. 1.7 Advanced Renal Cell Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC. • OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. • OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. 1.8 Classical Hodgkin Lymphoma • OPDIVO, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). • OPDIVO, as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after: • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. 1.9 Squamous Cell Carcinoma of the Head and Neck OPDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. 1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [see Clinical Studies (14.10) ] . OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.11 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) . • OPDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. 1.12 Hepatocellular Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. 1.13 Esophageal Cancer • OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). • OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] . • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] . • OPDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. 1.14 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
Full extracted label fields
- application numbers
- BLA125554
- boxed warning exact
- brand names
- OPDIVO
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- generic names
- NIVOLUMAB
- id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- indications and usage exact
- 1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). (1.8) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma. 1.2 Adjuvant Treatment of Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. 1.3 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). 1.4 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery. 1.5 Metastatic Non-Small Cell Lung Cancer • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations. • OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations. • OPDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. 1.6 Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. 1.7 Advanced Renal Cell Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC. • OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. • OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. 1.8 Classical Hodgkin Lymphoma • OPDIVO, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). • OPDIVO, as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after: • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. 1.9 Squamous Cell Carcinoma of the Head and Neck OPDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. 1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [see Clinical Studies (14.10) ] . OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.11 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) . • OPDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. 1.12 Hepatocellular Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. 1.13 Esophageal Cancer • OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). • OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] . • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] . • OPDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. 1.14 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- E.R. Squibb & Sons, L.L.C.
- matched search terms
- cancer
- carcinoma
- lymphoma
- melanoma
- tumor
- tumors
- malignant
- package ndcs
- 0003-3772-11
- 0003-3774-12
- 0003-3734-13
- 0003-3756-14
- product ndcs
- 0003-3734
- 0003-3772
- 0003-3774
- 0003-3756
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- Indications and Usage (1) 3/2026 Dosage and Administration (2) 3/2026 Warnings and Precautions (5) 5/2026
- record type
- complete_spl_indications_section_candidate
- routes
- INTRAVENOUS
- rxcuis
- 1657190
- 1657192
- 1657195
- 1657196
- 1991412
- 1991413
- 2569080
- 2569081
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00100.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 100
- total
- 830
- sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl effective time
- 20260812
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- substance names
- NIVOLUMAB
- uniis
- 31YO63LBSN
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
- fda_label_posted_after_spl_effective_date_requires_version_review
Drugs@FDA application source records
- application number
- BLA125554
- payload
- all indexed label documents
- Appl No
- 125554
- Application Docs Date
- 2016-05-17 00:00:00
- Application Docs ID
- 18936
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s019lbl.pdf
- Submission No
- 19
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2014-12-22 00:00:00
- Application Docs ID
- 39991
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125554lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- Appl No
- 125554
- Application Docs Date
- 2015-11-25 00:00:00
- Application Docs ID
- 39992
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s001lbl.pdf
- Submission No
- 1
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2015-10-09 00:00:00
- Application Docs ID
- 39993
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s005lbl.pdf
- Submission No
- 5
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2015-11-23 00:00:00
- Application Docs ID
- 39994
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s012lbl.pdf
- Submission No
- 12
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2016-09-28 00:00:00
- Application Docs ID
- 45403
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s017s018lbl.pdf
- Submission No
- 18
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2016-09-28 00:00:00
- Application Docs ID
- 45404
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s017s018lbl.pdf
- Submission No
- 17
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2016-10-06 00:00:00
- Application Docs ID
- 45501
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s016lbl.pdf
- Submission No
- 16
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2015-10-01 00:00:00
- Application Docs ID
- 45518
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s002lbl.pdf
- Submission No
- 2
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2016-11-10 00:00:00
- Application Docs ID
- 45897
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s022lbl.pdf
- Submission No
- 22
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2017-02-02 00:00:00
- Application Docs ID
- 47079
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s024lbl.pdf
- Submission No
- 24
- Submission Type
- SUPPL
- Appl No
- 125554
- Application Docs Date
- 2017-04-26 00:00:00
- Application Docs ID
- 48115
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s031lbl.pdf
- Submission No
- 31
- Submission Type
- SUPPL
- all submission records
- Appl No
- 125554
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 71
- Submission Status
- AP
- Submission Status Date
- 2020-11-10 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 72
- Submission Status
- AP
- Submission Status Date
- 2019-02-01 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 73
- Submission Status
- AP
- Submission Status Date
- 2019-05-02 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 75
- Submission Status
- AP
- Submission Status Date
- 2019-09-18 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 78
- Submission Status
- AP
- Submission Status Date
- 2020-03-10 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 80
- Submission Status
- AP
- Submission Status Date
- 2020-05-15 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 81
- Submission Status
- AP
- Submission Status Date
- 2020-06-10 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 82
- Submission Status
- AP
- Submission Status Date
- 2020-05-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 83
- Submission Status
- AP
- Submission Status Date
- 2020-06-23 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 84
- Submission Status
- AP
- Submission Status Date
- 2020-09-18 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 85
- Submission Status
- AP
- Submission Status Date
- 2020-09-18 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125554
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 86
- Submission Status
- AP
- Submission Status Date
- 2020-09-25 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- BLA125554
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554
- has approved submission record
- true
- latest approved submission date
- 2026-08-12
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 125554
- Application Docs Date
- 2026-08-18 00:00:00
- Application Docs ID
- 86953
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125554s138lbl.pdf#page=187
- Submission No
- 138
- Submission Type
- SUPPL
- official application record
- Appl No
- 125554
- Appl Public Notes
- Appl Type
- BLA
- Sponsor Name
- BRISTOL MYERS SQUIBB
- openfda application present
- true
- products
- Active Ingredient
- NIVOLUMAB
- Appl No
- 125554
- Drug Name
- OPDIVO
- Form
- INJECTABLE;INJECTION
- Product No
- 001
- Reference Drug
- 2
- Reference Standard
- Strength
- 40MG/4ML
- marketing status
- Prescription
Source passages and status connections
Passage 1 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 329
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pedi
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-1fd50a3e13a2b0c243c6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-4dd8fabe4674c26bc023
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 98
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 31
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 129
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 2 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 476
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-232dbbc4077204aab56f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-fa46b6a71c1062b6b4ea
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 98
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 31
- qualifier mentions
- context exact
- • adult and pediatric (12 years and older) patients with unresectab
- kind
- age
- polarity
- not_inferred
- span
- end
- 137
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 132
- context exact
- • adult and pediatric (12 years and older) patients with unresectable or metastat
- kind
- age
- polarity
- not_inferred
- span
- end
- 151
- end exclusive
- true
- exact text
- pediatric
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 142
- context exact
- • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a si
- kind
- age
- polarity
- not_inferred
- span
- end
- 171
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 153
- context exact
- ediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 222
- end exclusive
- true
- exact text
- metastatic melanoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 203
- context exact
- • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 222
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 187
- context exact
- d older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 275
- end exclusive
- true
- exact text
- as a single agent or in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 224
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 276
- end exclusive
- true
- exact text
- • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 130
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 3 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 482
- end exclusive
- true
- exact text
- ng antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 77
- current approval status
- not_reconciled
- duplicate text group
- dup-1b05dae3165b6ad6f6d0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-cf74cf1796b171e95f49
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 282
- end exclusive
- true
- exact text
- (1.1)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 277
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 4 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 642
- end exclusive
- true
- exact text
- ibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet c
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 83
- current approval status
- not_reconciled
- duplicate text group
- dup-192287cc79762d3a432a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-75f4dbeaaa30fab3f722
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 98
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 31
- qualifier mentions
- context exact
- • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely r
- kind
- age
- polarity
- not_inferred
- span
- end
- 320
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 315
- context exact
- • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stag
- kind
- age
- polarity
- not_inferred
- span
- end
- 343
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 325
- context exact
- for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, o
- kind
- age
- polarity
- not_inferred
- span
- end
- 362
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 344
- context exact
- • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage II
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 336
- end exclusive
- true
- exact text
- adjuvant treatment of adult and pediatric p
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 293
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 442
- end exclusive
- true
- exact text
- • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 283
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 5 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 683
- end exclusive
- true
- exact text
- r in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 243
- current approval status
- not_reconciled
- duplicate text group
- dup-b779e9a07dd8cc23072a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-731918d5c6a635617c74
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 483
- end exclusive
- true
- exact text
- (1.2) Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 443
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 6 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 854
- end exclusive
- true
- exact text
- for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with pla
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 284
- current approval status
- not_reconciled
- duplicate text group
- dup-b9643809985de84efe4e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-d95479a59de1470db910
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 98
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 31
- qualifier mentions
- context exact
- • adult patients with resectable (tumors ≥4 cm or node positive) non-small c
- kind
- age
- polarity
- not_inferred
- span
- end
- 500
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 486
- context exact
- • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in comb
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 551
- end exclusive
- true
- exact text
- resectable (tumors ≥4 cm or node positive) no
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 506
- context exact
- s ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 602
- end exclusive
- true
- exact text
- neoadjuvant setting
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 583
- context exact
- ive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 653
- end exclusive
- true
- exact text
- in combination with platinum-doublet chemotherapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 604
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 654
- end exclusive
- true
- exact text
- • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 484
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 7 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 860
- end exclusive
- true
- exact text
- all Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 455
- current approval status
- not_reconciled
- duplicate text group
- dup-81e51bc0f9b111739dc6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-92307ef1136916bebca0
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 660
- end exclusive
- true
- exact text
- (1.3)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 655
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 8 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1150
- end exclusive
- true
- exact text
- ll Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatmen
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 461
- current approval status
- not_reconciled
- duplicate text group
- dup-071bcae15d35ba5717ea
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-a8f45e32ec4e96b4d5c6
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 98
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 31
- qualifier mentions
- context exact
- • adult patients with resectable (tumors ≥4 cm or node positive) non-small c
- kind
- age
- polarity
- not_inferred
- span
- end
- 677
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 663
- context exact
- m or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-do
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 802
- end exclusive
- true
- exact text
- EGFR mutations or ALK rearrangements
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 766
- context exact
- • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 728
- end exclusive
- true
- exact text
- resectable (tumors ≥4 cm or node positive) no
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 683
- context exact
- ncer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followe
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 829
- end exclusive
- true
- exact text
- neoadjuvant treatment
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 808
- context exact
- um-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 949
- end exclusive
- true
- exact text
- adjuvant treatment after surgery
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 917
- context exact
- mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 949
- end exclusive
- true
- exact text
- in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 831
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 950
- end exclusive
- true
- exact text
- • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 661
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 9 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1156
- end exclusive
- true
- exact text
- r and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in c
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 751
- current approval status
- not_reconciled
- duplicate text group
- dup-f66506a39e239609584b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-a74c4542d84d07de10ac
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 956
- end exclusive
- true
- exact text
- (1.4)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 951
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1383
- end exclusive
- true
- exact text
- no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of pl
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 757
- current approval status
- not_reconciled
- duplicate text group
- dup-77897d54893806f4af39
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-612117e89d115227a41d
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with metastatic non-small cell lung cancer expressing PD‑L1
- kind
- age
- polarity
- not_inferred
- span
- end
- 973
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 959
- context exact
- • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, w
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1022
- end exclusive
- true
- exact text
- metastatic non-small cell lung cancer expre
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 979
- context exact
- D‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1126
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1089
- context exact
- • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, wit
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1024
- end exclusive
- true
- exact text
- metastatic non-small cell lung cancer express
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 979
- context exact
- zed test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 1182
- end exclusive
- true
- exact text
- first-line treatment in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1131
- context exact
- R or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1182
- end exclusive
- true
- exact text
- in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1152
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1183
- end exclusive
- true
- exact text
- • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 957
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1389
- end exclusive
- true
- exact text
- tatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 984
- current approval status
- not_reconciled
- duplicate text group
- dup-2eb9923c5d411787ac75
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-1a86b00cbc3e01c234fa
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1189
- end exclusive
- true
- exact text
- (1.5)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1184
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1611
- end exclusive
- true
- exact text
- non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease prog
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 990
- current approval status
- not_reconciled
- duplicate text group
- dup-2ca819aedff7684165a7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-35f5a6e484ce0e9e4668
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with metastatic or recurrent non-small cell lung cancer wit
- kind
- age
- polarity
- not_inferred
- span
- end
- 1206
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1192
- context exact
- • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as fir
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1255
- end exclusive
- true
- exact text
- metastatic or recurrent non-small cell lung
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1212
- context exact
- metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycl
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1315
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations as fir
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1271
- context exact
- • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1257
- end exclusive
- true
- exact text
- metastatic or recurrent non-small cell lung c
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1212
- context exact
- ung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 1410
- end exclusive
- true
- exact text
- first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1312
- context exact
- R or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1410
- end exclusive
- true
- exact text
- in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1334
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1411
- end exclusive
- true
- exact text
- • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1190
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1617
- end exclusive
- true
- exact text
- metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progressio
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1212
- current approval status
- not_reconciled
- duplicate text group
- dup-2eb9923c5d411787ac75
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-aed060e8d9c0100f7545
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1417
- end exclusive
- true
- exact text
- (1.5)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1412
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1734
- end exclusive
- true
- exact text
- atic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adu
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1218
- current approval status
- not_reconciled
- duplicate text group
- dup-bf2d56ba20e84c278776
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-bd7be97982a78264b18b
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with metastatic non-small cell lung cancer and progression
- kind
- age
- polarity
- not_inferred
- span
- end
- 1434
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1420
- context exact
- • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1483
- end exclusive
- true
- exact text
- metastatic non-small cell lung cancer and p
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1440
- context exact
- • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1485
- end exclusive
- true
- exact text
- metastatic non-small cell lung cancer and pro
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1440
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1534
- end exclusive
- true
- exact text
- • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1418
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1891
- end exclusive
- true
- exact text
- n combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adul
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1335
- current approval status
- not_reconciled
- duplicate text group
- dup-305410d924be72af31b5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-922fd105c45a64351f1b
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1593
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations should
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1549
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1691
- end exclusive
- true
- exact text
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1535
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1928
- end exclusive
- true
- exact text
- n on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1492
- current approval status
- not_reconciled
- duplicate text group
- dup-cb81e6668238fb37ddc0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-495639ddf38c5b975f49
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1728
- end exclusive
- true
- exact text
- (1.5) Malignant Pleural Mesothelioma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1692
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2051
- end exclusive
- true
- exact text
- rapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with a
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1529
- current approval status
- not_reconciled
- duplicate text group
- dup-95363e0e514579c0e62a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-4f6cb089a27a401eb897
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable malignant pleural mesothelioma, as first-
- kind
- age
- polarity
- not_inferred
- span
- end
- 1745
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1731
- context exact
- • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1794
- end exclusive
- true
- exact text
- unresectable malignant pleural mesothelioma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1751
- context exact
- tients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 1850
- end exclusive
- true
- exact text
- first-line treatment in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1799
- context exact
- ble malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1850
- end exclusive
- true
- exact text
- in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1820
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1851
- end exclusive
- true
- exact text
- • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1729
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 18 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2084
- end exclusive
- true
- exact text
- aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1652
- current approval status
- not_reconciled
- duplicate text group
- dup-6ab755630745c9c2060b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-4bd2900d5bdb823fbb1a
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 1884
- end exclusive
- true
- exact text
- (1.6) Renal Cell Carcinoma (RCC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1852
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 19 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2221
- end exclusive
- true
- exact text
- PDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prio
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1685
- current approval status
- not_reconciled
- duplicate text group
- dup-c38d0e2e14e434b47029
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-d733d4928edbf77d16b3
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with intermediate or poor risk advanced renal cell carcinom
- kind
- age
- polarity
- not_inferred
- span
- end
- 1901
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1887
- context exact
- • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1962
- end exclusive
- true
- exact text
- advanced renal cell carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1933
- context exact
- termediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2020
- end exclusive
- true
- exact text
- first-line treatment in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1969
- context exact
- sk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2020
- end exclusive
- true
- exact text
- in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1990
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2021
- end exclusive
- true
- exact text
- • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1885
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 20 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2227
- end exclusive
- true
- exact text
- combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1822
- current approval status
- not_reconciled
- duplicate text group
- dup-31a91af0de3fc9f105e5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-bb80679dab50f01e8221
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2027
- end exclusive
- true
- exact text
- (1.7)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2022
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 21 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2340
- end exclusive
- true
- exact text
- nation with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients w
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1828
- current approval status
- not_reconciled
- duplicate text group
- dup-808feb1b116fe6d491ba
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-cfce5fc9a23dfc326e36
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with advanced renal cell carcinoma, as a first-line treatme
- kind
- age
- polarity
- not_inferred
- span
- end
- 2044
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2030
- context exact
- • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2079
- end exclusive
- true
- exact text
- advanced renal cell carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2050
- context exact
- • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2139
- end exclusive
- true
- exact text
- first-line treatment in combination with cabozantinib
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2086
- context exact
- th advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2139
- end exclusive
- true
- exact text
- in combination with cabozantinib
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2107
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2140
- end exclusive
- true
- exact text
- • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2028
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 22 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2346
- end exclusive
- true
- exact text
- renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients with pr
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1941
- current approval status
- not_reconciled
- duplicate text group
- dup-31a91af0de3fc9f105e5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-9f6d0fa87ad6b686bc96
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2146
- end exclusive
- true
- exact text
- (1.7)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2141
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 23 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2447
- end exclusive
- true
- exact text
- cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinbl
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 1947
- current approval status
- not_reconciled
- duplicate text group
- dup-24e5628a62f9312a0491
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-5818f797b190fbcdfa87
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with advanced renal cell carcinoma who have received prior
- kind
- age
- polarity
- not_inferred
- span
- end
- 2163
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2149
- context exact
- • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2212
- end exclusive
- true
- exact text
- advanced renal cell carcinoma who have rece
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2169
- context exact
- • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2246
- end exclusive
- true
- exact text
- who have received prior anti-angiogenic therapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2199
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2247
- end exclusive
- true
- exact text
- • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2147
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 24 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2486
- end exclusive
- true
- exact text
- h advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). (1.8) •
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2048
- current approval status
- not_reconciled
- duplicate text group
- dup-4db7856b4545de79134d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-97640bdda557a3a5289d
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2286
- end exclusive
- true
- exact text
- (1.7) Classical Hodgkin Lymphoma (cHL)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2248
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 25 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2677
- end exclusive
- true
- exact text
- irst-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). (1.8) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2087
- current approval status
- not_reconciled
- duplicate text group
- dup-320d083d0ee94e5e9b3a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-8ce3a977922e5dd0addd
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult and pediatric (12 years and older) patients with previously
- kind
- age
- polarity
- not_inferred
- span
- end
- 2294
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2289
- context exact
- • adult and pediatric (12 years and older) patients with previously untreated, St
- kind
- age
- polarity
- not_inferred
- span
- end
- 2308
- end exclusive
- true
- exact text
- pediatric
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2299
- context exact
- • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classi
- kind
- age
- polarity
- not_inferred
- span
- end
- 2328
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2310
- context exact
- • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2476
- end exclusive
- true
- exact text
- previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2344
- context exact
- ously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2476
- end exclusive
- true
- exact text
- in combination with doxorubicin, vinblastine, and dacarbazine (AVD)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2409
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2477
- end exclusive
- true
- exact text
- • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD).
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2287
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 26 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2683
- end exclusive
- true
- exact text
- ma (cHL) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). (1.8) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2278
- current approval status
- not_reconciled
- duplicate text group
- dup-abafbc2501c588cbc455
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-bf11c6b121f0e0880e74
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2483
- end exclusive
- true
- exact text
- (1.8)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2478
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 27 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2777
- end exclusive
- true
- exact text
- L) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). (1.8) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Ne
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2284
- current approval status
- not_reconciled
- duplicate text group
- dup-47842cb2197b6fac88e2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-c20cbdd664efeb89aeb2
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with classical Hodgkin lymphoma that has relapsed or progre
- kind
- age
- polarity
- not_inferred
- span
- end
- 2500
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2486
- context exact
- • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8)
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2574
- end exclusive
- true
- exact text
- relapsed or progressed after: (1
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2542
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2577
- end exclusive
- true
- exact text
- • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2484
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 28 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2865
- end exclusive
- true
- exact text
- IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). (1.8) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2378
- current approval status
- not_reconciled
- duplicate text group
- dup-81b5986d0bfedef0579e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-cf1465224b1ae9eb108a
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2665
- end exclusive
- true
- exact text
- • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2578
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 29 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2934
- end exclusive
- true
- exact text
- zine (AVD). (1.8) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based t
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2466
- current approval status
- not_reconciled
- duplicate text group
- dup-5c3e2ab080379358b603
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-fbbec1ae4a496d238b87
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2734
- end exclusive
- true
- exact text
- • 3 or more lines of systemic therapy that includes autologous HSCT.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2666
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 30 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2987
- end exclusive
- true
- exact text
- at has relapsed or progressed after: (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatme
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2535
- current approval status
- not_reconciled
- duplicate text group
- dup-19344d4b6b8bd3c39f3a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-b71cca902ec8b4eacccc
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2787
- end exclusive
- true
- exact text
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2735
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 31 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3141
- end exclusive
- true
- exact text
- us hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients w
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2588
- current approval status
- not_reconciled
- duplicate text group
- dup-d7c79e509c3bda60cc69
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-c12ffcd0668d77deae84
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with recurrent or metastatic squamous cell carcinoma of the
- kind
- age
- polarity
- not_inferred
- span
- end
- 2804
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2790
- context exact
- • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2866
- end exclusive
- true
- exact text
- metastatic squamous cell carcinoma of the h
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2823
- context exact
- • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or afte
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2854
- end exclusive
- true
- exact text
- recurrent or metastatic squamous cell carcin
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2810
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2941
- end exclusive
- true
- exact text
- • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2788
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 32 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3168
- end exclusive
- true
- exact text
- s Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metasta
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2742
- current approval status
- not_reconciled
- duplicate text group
- dup-a723464c313956e97e60
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-441849eae5cf18da0c97
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 2968
- end exclusive
- true
- exact text
- (1.9) Urothelial Carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2942
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 33 · risk or warning
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 3315
- end exclusive
- true
- exact text
- d and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or m
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2769
- current approval status
- not_reconciled
- duplicate text group
- dup-3005a38f847640e57b9d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-87d7723259b8b9ff8790
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recu
- kind
- age
- polarity
- not_inferred
- span
- end
- 3007
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2993
- context exact
- • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3014
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with u
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2971
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3115
- end exclusive
- true
- exact text
- • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2969
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 34 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3322
- end exclusive
- true
- exact text
- a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastat
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2916
- current approval status
- not_reconciled
- duplicate text group
- dup-eac06f5f8b878da92e14
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-a28c226a74ebab65b679
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3122
- end exclusive
- true
- exact text
- (1.10)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3116
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 35 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3464
- end exclusive
- true
- exact text
- num-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression withi
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 2923
- current approval status
- not_reconciled
- duplicate text group
- dup-22845b0e89140a467260
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-1707342595251915d065
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable or metastatic urothelial carcinoma, as fi
- kind
- age
- polarity
- not_inferred
- span
- end
- 3139
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3125
- context exact
- • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3192
- end exclusive
- true
- exact text
- metastatic urothelial carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3161
- context exact
- • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3192
- end exclusive
- true
- exact text
- unresectable or metastatic urothelial carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3145
- context exact
- ts with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 3263
- end exclusive
- true
- exact text
- first-line treatment in combination with cisplatin and gemcitabine
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3197
- context exact
- or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 3263
- end exclusive
- true
- exact text
- in combination with cisplatin and gemcitabine
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3218
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3264
- end exclusive
- true
- exact text
- • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3123
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 36 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3471
- end exclusive
- true
- exact text
- currence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 mo
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3065
- current approval status
- not_reconciled
- duplicate text group
- dup-eac06f5f8b878da92e14
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-f517ec1b00c9ef85cc8b
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3271
- end exclusive
- true
- exact text
- (1.10)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3265
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 37 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3550
- end exclusive
- true
- exact text
- e after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3072
- current approval status
- not_reconciled
- duplicate text group
- dup-ad22cda225ea158a2343
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-a9b55ef31cf353479d94
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with locally advanced or metastatic urothelial carcinoma wh
- kind
- age
- polarity
- not_inferred
- span
- end
- 3288
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3274
- context exact
- • adult patients with locally advanced or metastatic urothelial carcinoma who:
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3350
- end exclusive
- true
- exact text
- metastatic urothelial carcinoma who:
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3314
- context exact
- • adult patients with locally advanced or metastatic urothelial carcinoma who:
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3345
- end exclusive
- true
- exact text
- locally advanced or metastatic urothelial carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3294
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3350
- end exclusive
- true
- exact text
- • adult patients with locally advanced or metastatic urothelial carcinoma who:
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3272
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 38 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3631
- end exclusive
- true
- exact text
- ctable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients wi
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3151
- current approval status
- not_reconciled
- duplicate text group
- dup-2cd3738c88d8a7d3d74a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-8e3232d0079e47dc1371
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3431
- end exclusive
- true
- exact text
- • have disease progression during or following platinum-containing chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3351
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 39 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3751
- end exclusive
- true
- exact text
- with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal can
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3232
- current approval status
- not_reconciled
- duplicate text group
- dup-64c36f6ff4b736322a80
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-446d63a81cd20ab15ed8
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3525
- end exclusive
- true
- exact text
- neoadjuvant or adjuvant treatment with platinu
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3479
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3551
- end exclusive
- true
- exact text
- • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3432
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 40 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3776
- end exclusive
- true
- exact text
- have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3352
- current approval status
- not_reconciled
- duplicate text group
- dup-ee53b0c47639cc2a582b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-7d10c23e36bb55c8b7b1
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3576
- end exclusive
- true
- exact text
- (1.10) Colorectal Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3552
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 41 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3992
- end exclusive
- true
- exact text
- during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3377
- current approval status
- not_reconciled
- duplicate text group
- dup-69f67aa096fa91842b56
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-6a17ad57d15542e75bd8
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult and pediatric (12 years and older) patients with unresectab
- kind
- age
- polarity
- not_inferred
- span
- end
- 3584
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3579
- context exact
- • adult and pediatric (12 years and older) patients with unresectable or metastat
- kind
- age
- polarity
- not_inferred
- span
- end
- 3598
- end exclusive
- true
- exact text
- pediatric
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3589
- context exact
- • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite in
- kind
- age
- polarity
- not_inferred
- span
- end
- 3618
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3600
- context exact
- ediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cance
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3693
- end exclusive
- true
- exact text
- metastatic microsatellite instability-high
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3650
- context exact
- unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3739
- end exclusive
- true
- exact text
- MSI-H) or mismatch repair deficient (dMMR) co
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3694
- context exact
- • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colo
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3681
- end exclusive
- true
- exact text
- unresectable or metastatic microsatellite insta
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3634
- context exact
- or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 3791
- end exclusive
- true
- exact text
- in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3761
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3792
- end exclusive
- true
- exact text
- • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3577
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 42 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3999
- end exclusive
- true
- exact text
- atric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatme
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3593
- current approval status
- not_reconciled
- duplicate text group
- dup-9a078e885b49fd63ca1d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-9605e33d28d3d25ceba6
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 3799
- end exclusive
- true
- exact text
- (1.11)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3793
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 43 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4255
- end exclusive
- true
- exact text
- 12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combinat
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3600
- current approval status
- not_reconciled
- duplicate text group
- dup-63b98dc0f4a423b34fca
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-cc06f70b512ffe39f5a9
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult and pediatric (12 years and older) patients with microsatel
- kind
- age
- polarity
- not_inferred
- span
- end
- 3807
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3802
- context exact
- • adult and pediatric (12 years and older) patients with microsatellite instabili
- kind
- age
- polarity
- not_inferred
- span
- end
- 3821
- end exclusive
- true
- exact text
- pediatric
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3812
- context exact
- • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or m
- kind
- age
- polarity
- not_inferred
- span
- end
- 3841
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3823
- context exact
- s and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following tre
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3935
- end exclusive
- true
- exact text
- MSI-H) or mismatch repair deficient (dMMR) me
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3890
- context exact
- nstability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3978
- end exclusive
- true
- exact text
- metastatic colorectal cancer that has progres
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3933
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4055
- end exclusive
- true
- exact text
- • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3800
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 44 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4295
- end exclusive
- true
- exact text
- microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients wi
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3856
- current approval status
- not_reconciled
- duplicate text group
- dup-1caf0ac44a14678d27cb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-18671f7f2204111a8461
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4095
- end exclusive
- true
- exact text
- ( 1.11 ) Hepatocellular Carcinoma (HCC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4056
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 45 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4434
- end exclusive
- true
- exact text
- or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with complet
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3896
- current approval status
- not_reconciled
- duplicate text group
- dup-6fb454fa2012dea1d4a4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-254dd38952d4cf26d35f
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable or metastatic hepatocellular carcinoma (H
- kind
- age
- polarity
- not_inferred
- span
- end
- 4112
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4098
- context exact
- • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4175
- end exclusive
- true
- exact text
- metastatic hepatocellular carcinoma (HCC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4134
- context exact
- • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ip
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4165
- end exclusive
- true
- exact text
- unresectable or metastatic hepatocellular carci
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4118
- context exact
- sectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4233
- end exclusive
- true
- exact text
- first-line treatment in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4182
- context exact
- c hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4233
- end exclusive
- true
- exact text
- in combination with ipilimumab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4203
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4234
- end exclusive
- true
- exact text
- • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4096
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 46 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4441
- end exclusive
- true
- exact text
- tin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely res
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4035
- current approval status
- not_reconciled
- duplicate text group
- dup-a813a621e5d53c57e377
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-39d3f14fa4685952f68f
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4241
- end exclusive
- true
- exact text
- (1.12)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4235
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 47 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4577
- end exclusive
- true
- exact text
- d irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4042
- current approval status
- not_reconciled
- duplicate text group
- dup-51091f06806bcfd79efa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-20353837c98d6aabf33f
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previousl
- kind
- age
- polarity
- not_inferred
- span
- end
- 4292
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4278
- context exact
- tion with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4357
- end exclusive
- true
- exact text
- metastatic HCC who have been previously tre
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4314
- context exact
- • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4345
- end exclusive
- true
- exact text
- unresectable or metastatic HCC who have been pr
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4298
- context exact
- patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4376
- end exclusive
- true
- exact text
- previously treated with sorafenib
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4343
- context exact
- • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4376
- end exclusive
- true
- exact text
- in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4244
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4377
- end exclusive
- true
- exact text
- • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4242
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 48 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4604
- end exclusive
- true
- exact text
- s a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patien
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4178
- current approval status
- not_reconciled
- duplicate text group
- dup-6a8e4a7d905c85349fed
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-24a56b1a8a81eb6e30b6
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4404
- end exclusive
- true
- exact text
- ( 1.12 ) Esophageal Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4378
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 49 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4782
- end exclusive
- true
- exact text
- combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4205
- current approval status
- not_reconciled
- duplicate text group
- dup-2c083e74197f4878a46a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-9e77a5a872a3d770286f
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with completely resected esophageal or gastroesophageal jun
- kind
- age
- polarity
- not_inferred
- span
- end
- 4421
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4407
- context exact
- cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4581
- end exclusive
- true
- exact text
- neoadjuvant chemoradiotherapy (CRT)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4546
- context exact
- sophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4581
- end exclusive
- true
- exact text
- who have received neoadjuvant chemoradiotherapy (CRT)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4528
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4582
- end exclusive
- true
- exact text
- • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4405
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 50 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4789
- end exclusive
- true
- exact text
- 2 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose t
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4383
- current approval status
- not_reconciled
- duplicate text group
- dup-f6a714a71aa50b292c2d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-c622c9739af3148f0338
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4589
- end exclusive
- true
- exact text
- (1.13)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4583
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 51 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5014
- end exclusive
- true
- exact text
- phageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • ad
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4390
- current approval status
- not_reconciled
- duplicate text group
- dup-652d191db55b7f2ed5f4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-4b8989fa67b12c1a773a
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamou
- kind
- age
- polarity
- not_inferred
- span
- end
- 4606
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4592
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimid
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4680
- end exclusive
- true
- exact text
- metastatic esophageal squamous cell carcino
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4637
- context exact
- - and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4813
- end exclusive
- true
- exact text
- PD-L1 (≥1)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4803
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combinati
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4659
- end exclusive
- true
- exact text
- unresectable advanced or metastatic esophageal
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4612
- context exact
- dvanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4813
- end exclusive
- true
- exact text
- first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4686
- context exact
- esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4813
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4707
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4814
- end exclusive
- true
- exact text
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1).
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4590
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 52 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5021
- end exclusive
- true
- exact text
- esectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult pat
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4615
- current approval status
- not_reconciled
- duplicate text group
- dup-f6a714a71aa50b292c2d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-b86c800d6c103dfbfd2f
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 4821
- end exclusive
- true
- exact text
- (1.13)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4815
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 53 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5202
- end exclusive
- true
- exact text
- le advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Can
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4622
- current approval status
- not_reconciled
- duplicate text group
- dup-4ea6c69fc546e5bd8eed
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-cb88768cf61b3d273e90
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamou
- kind
- age
- polarity
- not_inferred
- span
- end
- 4838
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4824
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab wh
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4912
- end exclusive
- true
- exact text
- metastatic esophageal squamous cell carcino
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4869
- context exact
- eatment in combination with ipilimumab whose tumors express PD-L1 (≥1).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5001
- end exclusive
- true
- exact text
- PD-L1 (≥1)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4991
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combinati
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4891
- end exclusive
- true
- exact text
- unresectable advanced or metastatic esophageal
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4844
- context exact
- dvanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 5001
- end exclusive
- true
- exact text
- first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4918
- context exact
- esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5001
- end exclusive
- true
- exact text
- in combination with ipilimumab whose tumors express PD-L1 (≥1)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4939
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 5002
- end exclusive
- true
- exact text
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1).
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4822
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 54 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5209
- end exclusive
- true
- exact text
- PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Ga
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4803
- current approval status
- not_reconciled
- duplicate text group
- dup-f6a714a71aa50b292c2d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-d78241a6961fa252a4d3
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 5009
- end exclusive
- true
- exact text
- (1.13)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5003
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 55 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5383
- end exclusive
- true
- exact text
- ≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal ad
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4810
- current approval status
- not_reconciled
- duplicate text group
- dup-4d7ffac68e9cf697c76f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-c561eeaf708d7618cd21
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable advanced, recurrent or metastatic esophag
- kind
- age
- polarity
- not_inferred
- span
- end
- 5026
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5012
- context exact
- • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based c
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5111
- end exclusive
- true
- exact text
- metastatic esophageal squamous cell carcino
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5068
- context exact
- • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5053
- end exclusive
- true
- exact text
- unresectable advanced
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5032
- context exact
- • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and plat
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5099
- end exclusive
- true
- exact text
- recurrent or metastatic esophageal squamous
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5055
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 5183
- end exclusive
- true
- exact text
- • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5010
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 56 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5470
- end exclusive
- true
- exact text
- xpress PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 4984
- current approval status
- not_reconciled
- duplicate text group
- dup-a506f42a1d288cad8068
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-fcea0c3701980a8cb9da
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 5270
- end exclusive
- true
- exact text
- (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5184
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 57 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5703
- end exclusive
- true
- exact text
- astatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unre
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5071
- current approval status
- not_reconciled
- duplicate text group
- dup-073f68f8c4142fec5f05
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-c9392dd8036987ae5a01
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with advanced or metastatic gastric cancer, gastroesophagea
- kind
- age
- polarity
- not_inferred
- span
- end
- 5287
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5273
- context exact
- • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarc
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5330
- end exclusive
- true
- exact text
- metastatic gastric cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5305
- context exact
- cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5462
- end exclusive
- true
- exact text
- PD-L1 (≥1) in combination with fluoropyrimidi
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5417
- context exact
- • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarc
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5330
- end exclusive
- true
- exact text
- advanced or metastatic gastric cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5293
- context exact
- d esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5502
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5428
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 5503
- end exclusive
- true
- exact text
- • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5271
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 58 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5710
- end exclusive
- true
- exact text
- metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectabl
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5304
- current approval status
- not_reconciled
- duplicate text group
- dup-54ae825ba082014efb95
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-ed453d4eb7b276213908
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 5510
- end exclusive
- true
- exact text
- (1.14)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5504
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 59 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 5935
- end exclusive
- true
- exact text
- atic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma. 1.2 Adjuvant Treatment of Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5311
- current approval status
- not_reconciled
- duplicate text group
- dup-a6980196fc65f69b4495
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-1fdb7216590078d4fc15
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 5624
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5612
- qualifier mentions
- context exact
- bination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable
- kind
- age
- polarity
- not_inferred
- span
- end
- 5651
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5646
- context exact
- ith ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma
- kind
- age
- polarity
- not_inferred
- span
- end
- 5674
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5656
- context exact
- indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 5693
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5675
- context exact
- 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is in
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5557
- end exclusive
- true
- exact text
- Metastatic Melanoma OPDIVO
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5531
- context exact
- pediatric patients 12 years and older with unresectable or metastatic melanoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5734
- end exclusive
- true
- exact text
- metastatic melanoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5715
- context exact
- 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is in
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5557
- end exclusive
- true
- exact text
- Unresectable or Metastatic Melanoma OPDIVO
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5515
- context exact
- ent of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5734
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5699
- context exact
- 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5734
- end exclusive
- true
- exact text
- as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5559
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 5735
- end exclusive
- true
- exact text
- 1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5511
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 60 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6148
- end exclusive
- true
- exact text
- tatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma. 1.2 Adjuvant Treatment of Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. 1.3 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5536
- current approval status
- not_reconciled
- duplicate text group
- dup-a21e2daf7a4c5e472cd8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-943bf4da82bc9fa65dbf
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 5790
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5778
- qualifier mentions
- context exact
- Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely r
- kind
- age
- polarity
- not_inferred
- span
- end
- 5826
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5821
- context exact
- OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stag
- kind
- age
- polarity
- not_inferred
- span
- end
- 5849
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5831
- context exact
- for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, o
- kind
- age
- polarity
- not_inferred
- span
- end
- 5868
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5850
- context exact
- 1.2 Adjuvant Treatment of Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric pa
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5783
- end exclusive
- true
- exact text
- Adjuvant Treatment of Melanoma OPDIVO is in
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5740
- context exact
- Adjuvant Treatment of Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage II
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5842
- end exclusive
- true
- exact text
- adjuvant treatment of adult and pediatric p
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5799
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 5948
- end exclusive
- true
- exact text
- 1.2 Adjuvant Treatment of Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5736
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 61 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6414
- end exclusive
- true
- exact text
- Treatment of Melanoma OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. 1.3 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). 1.4 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5749
- current approval status
- not_reconciled
- duplicate text group
- dup-e214e222b9c00ec580a4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-af0f5b538970f786e6b4
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 6087
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6075
- qualifier mentions
- context exact
- blet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small c
- kind
- age
- polarity
- not_inferred
- span
- end
- 6130
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6116
- context exact
- 1.3 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-double
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5999
- end exclusive
- true
- exact text
- Neoadjuvant Treatment of Resectable Non-Small
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5953
- context exact
- ination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lun
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6137
- end exclusive
- true
- exact text
- neoadjuvant treatment of adult patients with r
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6091
- context exact
- Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6203
- end exclusive
- true
- exact text
- in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung canc
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6024
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 6214
- end exclusive
- true
- exact text
- 1.3 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 5949
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 62 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6852
- end exclusive
- true
- exact text
- OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). 1.4 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery. 1.5 Metastatic Non-Small Cell Lung Cancer • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6015
- current approval status
- not_reconciled
- duplicate text group
- dup-6791987cb5ab3977eff9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-ceea676d23e31d03ac16
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 6366
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6354
- qualifier mentions
- context exact
- chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and n
- kind
- age
- polarity
- not_inferred
- span
- end
- 6414
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6400
- context exact
- itive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as a
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6560
- end exclusive
- true
- exact text
- EGFR) mutations or anaplastic lymphoma kinas
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6516
- context exact
- or receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment afte
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6582
- end exclusive
- true
- exact text
- ALK) rearrangements
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6563
- context exact
- 1.4 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with pl
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6265
- end exclusive
- true
- exact text
- Neoadjuvant and Adjuvant Treatment of Resectab
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6219
- context exact
- on with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6421
- end exclusive
- true
- exact text
- neoadjuvant treatment of adult patients with r
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6375
- context exact
- se (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6651
- end exclusive
- true
- exact text
- adjuvant treatment after surgery
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6619
- context exact
- Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplas
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6482
- end exclusive
- true
- exact text
- in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6303
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 6652
- end exclusive
- true
- exact text
- 1.4 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6215
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 63 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 6894
- end exclusive
- true
- exact text
- positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery. 1.5 Metastatic Non-Small Cell Lung Cancer • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [s
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6453
- current approval status
- not_reconciled
- duplicate text group
- dup-341ec24d6988e1633e90
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-4c33fd021c0f4dddd673
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.5 Metastatic Non-Small Cell Lung Cancer
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6694
- end exclusive
- true
- exact text
- Metastatic Non-Small Cell Lung Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6657
- context exact
- 1.5 Metastatic Non-Small Cell Lung Cancer
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6694
- end exclusive
- true
- exact text
- Metastatic Non-Small Cell Lung Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6657
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 6694
- end exclusive
- true
- exact text
- 1.5 Metastatic Non-Small Cell Lung Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6653
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 64 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7179
- end exclusive
- true
- exact text
- wth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery. 1.5 Metastatic Non-Small Cell Lung Cancer • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations. • OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6495
- current approval status
- not_reconciled
- duplicate text group
- dup-3fd8d15f654129e9062b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-ba3bfe57985a3bfc8925
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 6749
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6737
- qualifier mentions
- context exact
- th ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as d
- kind
- age
- polarity
- not_inferred
- span
- end
- 6796
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6782
- context exact
- dicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage a
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6845
- end exclusive
- true
- exact text
- metastatic NSCLC whose tumors express PD-L1
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6802
- context exact
- rized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6978
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6941
- context exact
- dicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6847
- end exclusive
- true
- exact text
- metastatic NSCLC whose tumors express PD-L1 (
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6802
- context exact
- PDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 6925
- end exclusive
- true
- exact text
- first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6758
- context exact
- • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGF
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6884
- end exclusive
- true
- exact text
- in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authoriz
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6705
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 6979
- end exclusive
- true
- exact text
- • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6695
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 65 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7410
- end exclusive
- true
- exact text
- f adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations. • OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations. • OPDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should ha
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6780
- current approval status
- not_reconciled
- duplicate text group
- dup-3a86d923af7a1b3cd639
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-2a45bdfeddaa2b020414
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 7080
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7068
- qualifier mentions
- context exact
- chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK gen
- kind
- age
- polarity
- not_inferred
- span
- end
- 7127
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7113
- context exact
- dicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7162
- end exclusive
- true
- exact text
- metastatic or recurrent NSCLC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7133
- context exact
- adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7209
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7172
- context exact
- dicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7162
- end exclusive
- true
- exact text
- metastatic or recurrent NSCLC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7133
- context exact
- cles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 7209
- end exclusive
- true
- exact text
- first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7089
- context exact
- • OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7169
- end exclusive
- true
- exact text
- in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6990
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 7210
- end exclusive
- true
- exact text
- • OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 6980
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 66 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7548
- end exclusive
- true
- exact text
- pilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations. • OPDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. 1.6 Malignant Pleural Mesothelioma OPDIVO,
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7011
- current approval status
- not_reconciled
- duplicate text group
- dup-11f5ae1544a43f816679
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-881a7d2bac6b344ab81c
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 7232
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7220
- qualifier mentions
- context exact
- • OPDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum
- kind
- age
- polarity
- not_inferred
- span
- end
- 7268
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7254
- context exact
- PDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7317
- end exclusive
- true
- exact text
- metastatic NSCLC with progression on or aft
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7274
- context exact
- PDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7319
- end exclusive
- true
- exact text
- metastatic NSCLC with progression on or after
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7274
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 7348
- end exclusive
- true
- exact text
- • OPDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7211
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 67 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7705
- end exclusive
- true
- exact text
- current NSCLC, with no EGFR or ALK genomic tumor aberrations. • OPDIVO is indicated for the treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. 1.6 Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. 1.7 Advanced R
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7149
- current approval status
- not_reconciled
- duplicate text group
- dup-305410d924be72af31b5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-21f257f23a5969db81eb
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7407
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations should
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7363
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 7505
- end exclusive
- true
- exact text
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7349
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 68 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7890
- end exclusive
- true
- exact text
- n on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. 1.6 Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. 1.7 Advanced Renal Cell Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC. • OPDIVO, in combi
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7306
- current approval status
- not_reconciled
- duplicate text group
- dup-cc5b552a1e52290e05fe
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-9809b66514b2cca22c4f
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 7593
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7581
- qualifier mentions
- context exact
- th ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 7640
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7626
- context exact
- dicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7689
- end exclusive
- true
- exact text
- unresectable malignant pleural mesothelioma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7646
- context exact
- PDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 7689
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable malignant pleural mesothelioma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7602
- context exact
- 1.6 Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7689
- end exclusive
- true
- exact text
- in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7549
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 7690
- end exclusive
- true
- exact text
- 1.6 Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7506
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 69 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7924
- end exclusive
- true
- exact text
- eiving OPDIVO. 1.6 Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. 1.7 Advanced Renal Cell Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC. • OPDIVO, in combination with cabozantinib, is indic
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7491
- current approval status
- not_reconciled
- duplicate text group
- dup-123c6affd26a77e2f5b4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-8e545c6374f03522f5e3
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.7 Advanced Renal Cell Carcinoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7724
- end exclusive
- true
- exact text
- Advanced Renal Cell Carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7695
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 7724
- end exclusive
- true
- exact text
- 1.7 Advanced Renal Cell Carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7691
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 70 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 8071
- end exclusive
- true
- exact text
- al Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. 1.7 Advanced Renal Cell Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC. • OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. • OPDIVO, as a single agent, is indicated for the treatment of adult patient
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7525
- current approval status
- not_reconciled
- duplicate text group
- dup-d431ab77e9531c3da144
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-48a6fdb7bca20c96c434
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 7779
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7767
- qualifier mentions
- context exact
- th ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 7826
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7812
- context exact
- treatment of adult patients with intermediate or poor risk advanced RCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7870
- end exclusive
- true
- exact text
- advanced RCC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7858
- context exact
- PDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 7870
- end exclusive
- true
- exact text
- first-line treatment of adult patients with intermediate or poor risk advanced RCC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7788
- context exact
- • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7870
- end exclusive
- true
- exact text
- in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7735
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 7871
- end exclusive
- true
- exact text
- • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7725
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 71 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 8194
- end exclusive
- true
- exact text
- ural mesothelioma. 1.7 Advanced Renal Cell Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced RCC. • OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. • OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. 1.8 Classical Hodgkin Lymphoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7672
- current approval status
- not_reconciled
- duplicate text group
- dup-215fdb36239390623ca0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-e442a9efb9391faf40a7
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 7928
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7916
- qualifier mentions
- context exact
- cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 7975
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7961
- context exact
- dicated for the first-line treatment of adult patients with advanced RCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7993
- end exclusive
- true
- exact text
- advanced RCC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7981
- context exact
- IVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 7993
- end exclusive
- true
- exact text
- first-line treatment of adult patients with advanced RCC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7937
- context exact
- • OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7993
- end exclusive
- true
- exact text
- in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7882
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 7994
- end exclusive
- true
- exact text
- • OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7872
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 72 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 8362
- end exclusive
- true
- exact text
- ine treatment of adult patients with intermediate or poor risk advanced RCC. • OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. • OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. 1.8 Classical Hodgkin Lymphoma • OPDIVO, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with pr
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7795
- current approval status
- not_reconciled
- duplicate text group
- dup-8cf29a867d5a0ad888b8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-1c473dd7518a16cf1de2
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 8036
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8024
- qualifier mentions
- context exact
- PDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received
- kind
- age
- polarity
- not_inferred
- span
- end
- 8072
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8058
- context exact
- gent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8121
- end exclusive
- true
- exact text
- advanced renal cell carcinoma (RCC) who hav
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8078
- context exact
- of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 8161
- end exclusive
- true
- exact text
- who have received prior anti-angiogenic therapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8114
- context exact
- • OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8161
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8005
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 8162
- end exclusive
- true
- exact text
- • OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7995
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 73 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8393
- end exclusive
- true
- exact text
- ult patients with advanced RCC. • OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. 1.8 Classical Hodgkin Lymphoma • OPDIVO, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III o
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7963
- current approval status
- not_reconciled
- duplicate text group
- dup-594789bafdbb68a9d536
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-bd84f20906f4de12bab2
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 8193
- end exclusive
- true
- exact text
- 1.8 Classical Hodgkin Lymphoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8163
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 74 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 8631
- end exclusive
- true
- exact text
- • OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. 1.8 Classical Hodgkin Lymphoma • OPDIVO, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). • OPDIVO, as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after: • autologous hematopoietic stem cell transpl
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 7994
- current approval status
- not_reconciled
- duplicate text group
- dup-20372518de08751e4681
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-4dd12976c3b4c13f20e4
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 8285
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8273
- qualifier mentions
- context exact
- e, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously u
- kind
- age
- polarity
- not_inferred
- span
- end
- 8312
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8307
- context exact
- arbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or
- kind
- age
- polarity
- not_inferred
- span
- end
- 8335
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8317
- context exact
- indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgki
- kind
- age
- polarity
- not_inferred
- span
- end
- 8354
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8336
- context exact
- ent of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 8430
- end exclusive
- true
- exact text
- previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8360
- context exact
- • OPDIVO, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8383
- end exclusive
- true
- exact text
- in combination with doxorubicin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, S
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8204
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 8431
- end exclusive
- true
- exact text
- • OPDIVO, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8194
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 75 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 8786
- end exclusive
- true
- exact text
- cin, vinblastine, and dacarbazine (AVD), is indicated for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). • OPDIVO, as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after: • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. 1.9 Squamous Cell Carcinoma of the Head an
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8232
- current approval status
- not_reconciled
- duplicate text group
- dup-b04efd19b5cac04d9c3f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-b2fab8f571eb5166f6e1
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 8473
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8461
- qualifier mentions
- context exact
- PDIVO, as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or
- kind
- age
- polarity
- not_inferred
- span
- end
- 8509
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8495
- context exact
- ult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after:
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8586
- end exclusive
- true
- exact text
- relapsed or progressed after:
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8557
- context exact
- • OPDIVO, as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after:
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8586
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after:
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8442
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 8586
- end exclusive
- true
- exact text
- • OPDIVO, as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after:
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8432
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 76 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8874
- end exclusive
- true
- exact text
- III or IV classical Hodgkin lymphoma (cHL). • OPDIVO, as a single agent, is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after: • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. 1.9 Squamous Cell Carcinoma of the Head and Neck OPDIVO is indicated for the treatment of adult patients with recurrent or metasta
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8387
- current approval status
- not_reconciled
- duplicate text group
- dup-81b5986d0bfedef0579e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-27b5b182b33614d782e2
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 8674
- end exclusive
- true
- exact text
- • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8587
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 77 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8943
- end exclusive
- true
- exact text
- or the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after: • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. 1.9 Squamous Cell Carcinoma of the Head and Neck OPDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8475
- current approval status
- not_reconciled
- duplicate text group
- dup-5c3e2ab080379358b603
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-dccc49221e110b0f82bb
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 8743
- end exclusive
- true
- exact text
- • 3 or more lines of systemic therapy that includes autologous HSCT.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8675
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 78 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 9191
- end exclusive
- true
- exact text
- HL) that has relapsed or progressed after: • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. 1.9 Squamous Cell Carcinoma of the Head and Neck OPDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. 1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8544
- current approval status
- not_reconciled
- duplicate text group
- dup-57604576874d7350f9bb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-67e6d9e6bdea8ac51c3f
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 8812
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8800
- qualifier mentions
- context exact
- the Head and Neck OPDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the
- kind
- age
- polarity
- not_inferred
- span
- end
- 8848
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8834
- context exact
- cated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after pl
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 8910
- end exclusive
- true
- exact text
- metastatic squamous cell carcinoma of the h
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8867
- context exact
- PDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8898
- end exclusive
- true
- exact text
- recurrent or metastatic squamous cell carcin
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8854
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 8991
- end exclusive
- true
- exact text
- 1.9 Squamous Cell Carcinoma of the Head and Neck OPDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8744
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 79 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- positive_statement_also_contains_qualification_review_required
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 9423
- end exclusive
- true
- exact text
- OPDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. 1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [see Clinical Studies (14.10) ] . OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. OPDIVO is indicated for the tr
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8792
- current approval status
- not_reconciled
- duplicate text group
- dup-3b55c80abe2fc87f2d22
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-1fef44f7e4853a0ccf36
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 9037
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9025
- qualifier mentions
- context exact
- Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recu
- kind
- age
- polarity
- not_inferred
- span
- end
- 9082
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9068
- context exact
- 1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9089
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with u
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9046
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 9223
- end exclusive
- true
- exact text
- 1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [see Clinical Studies (14.10) ] .
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 8992
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 80 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 9592
- end exclusive
- true
- exact text
- is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [see Clinical Studies (14.10) ] . OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9024
- current approval status
- not_reconciled
- duplicate text group
- dup-b4e056c517ae253f8b11
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-32b1a802cd2d7c953331
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 9291
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9279
- qualifier mentions
- context exact
- d gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 9338
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9324
- context exact
- first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9391
- end exclusive
- true
- exact text
- metastatic urothelial carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9360
- context exact
- dicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9391
- end exclusive
- true
- exact text
- unresectable or metastatic urothelial carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9344
- context exact
- nation with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 9391
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9300
- context exact
- OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 9391
- end exclusive
- true
- exact text
- in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9232
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 9392
- end exclusive
- true
- exact text
- OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9224
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 81 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 9710
- end exclusive
- true
- exact text
- e Clinical Studies (14.10) ] . OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9193
- current approval status
- not_reconciled
- duplicate text group
- dup-a2aaccf469348f6e195d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-b42952f8da4df16c775f
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 9412
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9400
- qualifier mentions
- context exact
- OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma wh
- kind
- age
- polarity
- not_inferred
- span
- end
- 9448
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9434
- context exact
- or the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9510
- end exclusive
- true
- exact text
- metastatic urothelial carcinoma who:
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9474
- context exact
- PDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9505
- end exclusive
- true
- exact text
- locally advanced or metastatic urothelial carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9454
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 9510
- end exclusive
- true
- exact text
- OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9393
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 82 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 9791
- end exclusive
- true
- exact text
- treatment of adult patients with unresectable or metastatic urothelial carcinoma. OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.11 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Co
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9311
- current approval status
- not_reconciled
- duplicate text group
- dup-2cd3738c88d8a7d3d74a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-2968fcc0d368d818a0ea
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 9591
- end exclusive
- true
- exact text
- • have disease progression during or following platinum-containing chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9511
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 83 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 9911
- end exclusive
- true
- exact text
- OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.11 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9392
- current approval status
- not_reconciled
- duplicate text group
- dup-64c36f6ff4b736322a80
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-c29cb66adfb1252270bd
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9685
- end exclusive
- true
- exact text
- neoadjuvant or adjuvant treatment with platinu
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9639
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 9711
- end exclusive
- true
- exact text
- • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9592
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 84 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10006
- end exclusive
- true
- exact text
- have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.11 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9512
- current approval status
- not_reconciled
- duplicate text group
- dup-80e1788cca8d890fb5ea
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-259026a739ed10e2c639
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- icrosatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9806
- end exclusive
- true
- exact text
- Metastatic Colorectal Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9778
- context exact
- icrosatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9806
- end exclusive
- true
- exact text
- Metastatic Colorectal Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9778
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 9806
- end exclusive
- true
- exact text
- 1.11 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9712
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 85 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 10264
- end exclusive
- true
- exact text
- progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.11 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) . • OPDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metasta
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9607
- current approval status
- not_reconciled
- duplicate text group
- dup-46ad2cb48cc14fceb316
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-74d0e6b0f9f25a69bc9a
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 9861
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9849
- qualifier mentions
- context exact
- bination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable
- kind
- age
- polarity
- not_inferred
- span
- end
- 9888
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9883
- context exact
- ith ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsat
- kind
- age
- polarity
- not_inferred
- span
- end
- 9911
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9893
- context exact
- indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-
- kind
- age
- polarity
- not_inferred
- span
- end
- 9930
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9912
- context exact
- pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cance
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9995
- end exclusive
- true
- exact text
- metastatic microsatellite instability-high
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9952
- context exact
- unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10041
- end exclusive
- true
- exact text
- MSI-H) or mismatch repair deficient (dMMR) co
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9996
- context exact
- ent of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colo
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9983
- end exclusive
- true
- exact text
- unresectable or metastatic microsatellite insta
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9936
- context exact
- • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 9996
- end exclusive
- true
- exact text
- in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9817
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 10064
- end exclusive
- true
- exact text
- • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) .
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9807
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 86 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 10585
- end exclusive
- true
- exact text
- the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) . • OPDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. 1.12 Hepatocellular Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). • O
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 9865
- current approval status
- not_reconciled
- duplicate text group
- dup-ad9c5dab2b4a3bd34b5f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-c792b5d70a7b8803741d
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 10106
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10094
- qualifier mentions
- context exact
- PDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatelli
- kind
- age
- polarity
- not_inferred
- span
- end
- 10133
- end exclusive
- true
- exact text
- adult
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10128
- context exact
- a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MS
- kind
- age
- polarity
- not_inferred
- span
- end
- 10156
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10138
- context exact
- indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch re
- kind
- age
- polarity
- not_inferred
- span
- end
- 10175
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10157
- context exact
- ts 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed followi
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10259
- end exclusive
- true
- exact text
- MSI-H) or mismatch repair deficient (dMMR) me
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10214
- context exact
- nstability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxali
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10302
- end exclusive
- true
- exact text
- metastatic colorectal cancer (CRC) that has p
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10257
- context exact
- • OPDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10252
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (d
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10075
- regulatory links
- candidate source span
- end
- 10385
- end exclusive
- true
- exact text
- • OPDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10065
- fda indication exact
- For the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
- fda source row index
- 15
- fda source sha256
- 91f921503728c2afb0ec500d9c6034553e0b81d5af260a20c5478686c1127a7e
- fda status record id
- fda-aa-57a457367471d7ab21dc
- interpretation
- Source wording correspondence to a dated FDA status row; current approval not certified
- match method
- whole_indication_literal_normalized_substring
- matching review status
- source_comparison_only_clinical_review_pending
- scope relationship
- whole_fda_indication_text_present
- status category
- verified_clinical_benefit
- status event date
- 2025-04-08
- supporting anchor spans
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 10385
- end exclusive
- true
- exact text
- • OPDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10065
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Read indication-specific status → · whole_fda_indication_text_present
Passage 87 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10615
- end exclusive
- true
- exact text
- satellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. 1.12 Hepatocellular Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). • OPDIVO, in combination with ipi
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10186
- current approval status
- not_reconciled
- duplicate text group
- dup-9c0028b336730511cfa2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-ed865accef7264fc69c8
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 10415
- end exclusive
- true
- exact text
- 1.12 Hepatocellular Carcinoma
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10386
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 88 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 10781
- end exclusive
- true
- exact text
- I-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. 1.12 Hepatocellular Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. 1.13 Esophageal Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10216
- current approval status
- not_reconciled
- duplicate text group
- dup-a1e86304285f699e0a11
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-68e538cdea68c7e74914
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 10470
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10458
- qualifier mentions
- context exact
- th ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (H
- kind
- age
- polarity
- not_inferred
- span
- end
- 10517
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10503
- context exact
- first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10580
- end exclusive
- true
- exact text
- metastatic hepatocellular carcinoma (HCC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10539
- context exact
- dicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10570
- end exclusive
- true
- exact text
- unresectable or metastatic hepatocellular carci
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10523
- context exact
- PDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 10580
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10479
- context exact
- • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10580
- end exclusive
- true
- exact text
- in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10426
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 10581
- end exclusive
- true
- exact text
- • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10416
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 89 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 10957
- end exclusive
- true
- exact text
- an. 1.12 Hepatocellular Carcinoma • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. 1.13 Esophageal Cancer • OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who ha
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10382
- current approval status
- not_reconciled
- duplicate text group
- dup-a07a6487ed7567c949ff
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-eb9bc9248b3fb94a1150
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 10636
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10624
- qualifier mentions
- context exact
- bination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previousl
- kind
- age
- polarity
- not_inferred
- span
- end
- 10672
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10658
- context exact
- ed for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10737
- end exclusive
- true
- exact text
- metastatic HCC who have been previously tre
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10694
- context exact
- umab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10725
- end exclusive
- true
- exact text
- unresectable or metastatic HCC who have been pr
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10678
- context exact
- patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 10756
- end exclusive
- true
- exact text
- previously treated with sorafenib
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10723
- context exact
- • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10756
- end exclusive
- true
- exact text
- in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10592
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 10757
- end exclusive
- true
- exact text
- • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10582
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 90 · unclassified context
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10980
- end exclusive
- true
- exact text
- llular carcinoma (HCC). • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. 1.13 Esophageal Cancer • OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10558
- current approval status
- not_reconciled
- duplicate text group
- dup-159343f19afa098d196c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-0591a9c53a11270c50f8
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 10780
- end exclusive
- true
- exact text
- 1.13 Esophageal Cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10758
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 91 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11205
- end exclusive
- true
- exact text
- • OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. 1.13 Esophageal Cancer • OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). • OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal s
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10581
- current approval status
- not_reconciled
- duplicate text group
- dup-4728cff92e156ed7e29e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-75c5f3b77049d17af2e1
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 10802
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10790
- qualifier mentions
- context exact
- phageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- age
- polarity
- not_inferred
- span
- end
- 10950
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10936
- context exact
- • OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10854
- end exclusive
- true
- exact text
- adjuvant treatment of completely resected e
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10811
- context exact
- dual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11004
- end exclusive
- true
- exact text
- neoadjuvant chemoradiotherapy (CRT)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10969
- context exact
- n cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 11004
- end exclusive
- true
- exact text
- who have received neoadjuvant chemoradiotherapy (CRT)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10951
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 11005
- end exclusive
- true
- exact text
- • OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10781
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 92 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11507
- end exclusive
- true
- exact text
- the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). • OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] . • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors e
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 10806
- current approval status
- not_reconciled
- duplicate text group
- dup-2c83e9116491b3c07826
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-4b5391278ad67b769418
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 11104
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11092
- qualifier mentions
- context exact
- chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamou
- kind
- age
- polarity
- not_inferred
- span
- end
- 11151
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11137
- context exact
- e treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Ad
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11225
- end exclusive
- true
- exact text
- metastatic esophageal squamous cell carcino
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11182
- context exact
- phageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11300
- end exclusive
- true
- exact text
- PD-L1 (≥1) [see Dosage and Administration (2
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11256
- context exact
- dicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11204
- end exclusive
- true
- exact text
- unresectable advanced or metastatic esophageal
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11157
- context exact
- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 11283
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11113
- context exact
- • OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 11195
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic es
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11016
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 11307
- end exclusive
- true
- exact text
- • OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11006
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 93 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11765
- end exclusive
- true
- exact text
- the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] . • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] . • OPDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-base
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11108
- current approval status
- not_reconciled
- duplicate text group
- dup-ed174c8b7de90683bc30
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-98338891ac17ff278645
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 11362
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11350
- qualifier mentions
- context exact
- th ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamou
- kind
- age
- polarity
- not_inferred
- span
- end
- 11409
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11395
- context exact
- e treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Ad
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11483
- end exclusive
- true
- exact text
- metastatic esophageal squamous cell carcino
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11440
- context exact
- phageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11558
- end exclusive
- true
- exact text
- PD-L1 (≥1) [see Dosage and Administration (2
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11514
- context exact
- dicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11462
- end exclusive
- true
- exact text
- unresectable advanced or metastatic esophageal
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11415
- context exact
- PDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 11541
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11371
- context exact
- • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 11497
- end exclusive
- true
- exact text
- in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whos
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11318
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 11565
- end exclusive
- true
- exact text
- • OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11308
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 94 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11980
- end exclusive
- true
- exact text
- the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] . • OPDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. 1.14 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11366
- current approval status
- not_reconciled
- duplicate text group
- dup-f04337e43ed9317ae523
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-83c8a158fbaf3495f422
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 11587
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11575
- qualifier mentions
- context exact
- • OPDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophag
- kind
- age
- polarity
- not_inferred
- span
- end
- 11623
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11609
- context exact
- of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based c
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11708
- end exclusive
- true
- exact text
- metastatic esophageal squamous cell carcino
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11665
- context exact
- PDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11650
- end exclusive
- true
- exact text
- unresectable advanced
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11629
- context exact
- the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and plat
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11696
- end exclusive
- true
- exact text
- recurrent or metastatic esophageal squamous
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11652
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 11780
- end exclusive
- true
- exact text
- • OPDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11566
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 95 · positive indication candidate
- application numbers
- BLA125554
- brand names
- OPDIVO
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 12179
- end exclusive
- true
- exact text
- icated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. 1.14 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11581
- current approval status
- not_reconciled
- duplicate text group
- dup-0b4ed25fbf3c6f1d0d71
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB
- id
- ind-span-3ea5c7adc70d1bc4b034
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- positive predicate support span
- end
- 11962
- end exclusive
- true
- exact text
- is indicated
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11950
- qualifier mentions
- context exact
- -containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophagea
- kind
- age
- polarity
- not_inferred
- span
- end
- 11998
- end exclusive
- true
- exact text
- adult patients
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11984
- context exact
- icated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarc
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12041
- end exclusive
- true
- exact text
- metastatic gastric cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 12016
- context exact
- cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12172
- end exclusive
- true
- exact text
- PD-L1 (≥1) [see Dosage and Administration (2
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 12128
- context exact
- rapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarc
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 12041
- end exclusive
- true
- exact text
- advanced or metastatic gastric cancer
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 12004
- context exact
- geal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 12053
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesop
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11874
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 483
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 449
- abbreviation
- CRC
- definition exact
- colorectal cancer
- definition span
- end
- 3760
- end exclusive
- true
- exact text
- colorectal cancer (CRC)
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 3737
- source span
- end
- 12179
- end exclusive
- true
- exact text
- 1.14 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.1) ] .
- label id
- 1fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 26eb0583e63f8a27943a9a4f86da103eb1299c470279d992a424213286c89343
- start
- 11781
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221fce9e6a-6a7c-4fc0-a3a4-a0099f7bd2ce%22
- spl effective date
- 2026-08-12
- spl set id
- f570b9c4-6846-4de2-abfa-4d0a4ae4e394
- spl version
- 68
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Preserved source evidence · Not medical advice
Triangle